VIENNA, Va.--(BUSINESS WIRE)--CEL-SCI Corporation (NYSE MKT: CVM) (“CEL SCI” or the “Company”) reported financial results today for the fiscal year ended September 30, 2015. The Company also reported key clinical and corporate developments achieved during and subsequent to fiscal 2015.
Clinical and Corporate Developments Included:
• CEL-SCI raised net proceeds of approximately $21.15 million during fiscal 2015 and an additional $10.6 million subsequent to the end of the fiscal year, to finance its expanding Phase 3 trial in the treatment of head and neck cancer.
